Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01466660) enrolled 319 people with lung cancer — 160 in the afatinib group and 159 in the gefitinib group. The trial was measuring how long participants went without their disease getting worse (called progression-free survival), how long they stayed on their treatment (time to treatment failure), and how long they lived overall (overall survival). It also looked at how many participants' tumours shrank or disappeared, and for how long. The reported data shows that, for the main measure of how long disease stayed stable, the afatinib group had a median of about 12.8 months compared with about 11.2 months in the gefitinib group. (A "median" simply means the middle value — half of participants had a longer time and half had a shorter time.) For how long participants stayed on treatment, the reported medians were about 13.7 months for afatinib and about 11.5 months for gefitinib. For overall survival, the reported median figures were about 27.9 months in the afatinib group and about 24.5 months in the gefitinib group. Regarding tumour response, the reported data shows that approximately 79% of participants in the afatinib group and approximately 75% in the gefitinib group had their tumour shrink or disappear, with that response lasting a median of about 11.9 months and 11.1 months respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Lung Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with advanced lung cancer (stage IIIB or IV) of a specific type called adenocarcinoma, confirmed by a lab test.
- Your tumour has been tested and found to have a specific gene change (mutation) in the EGFR gene, specifically called Del19 and/or L858R.
- You have at least one tumour that can be measured on a scan.
- You are generally well enough to carry out light activity and care for yourself (your doctor will assess this using a standard scale).
- You are 18 years of age or older.
- Your liver, kidneys, and blood cell counts are within acceptable ranges based on recent blood tests.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have already had chemotherapy for advanced (stage IIIB or IV) lung cancer (earlier chemotherapy for a different stage may be allowed if it was more than 12 months ago).
- You have previously been treated with medicines that target the EGFR gene (small molecule drugs or antibodies).
- You had major surgery within the last 4 weeks.
- You currently have active cancer spread to the brain.
- You have cancer that has spread to the membranes surrounding the brain or spinal cord.
- You have or have had another type of cancer, with some exceptions such as certain treated skin cancers or cancers that have been fully in remission for more than 3 years (confirm with trial site).
- You have a known pre-existing lung condition called interstitial lung disease.
- You have significant heart or cardiovascular problems, as assessed by your doctor.
- Your heart's pumping function is below the normal range for the hospital running the trial.
- You are a woman who could become pregnant, or a man who could father a child, and you are unwilling to use reliable contraception or remain abstinent during the trial and for at least 2 months after treatment ends.
- You are currently pregnant or breastfeeding.
- You have active hepatitis or are known to carry the HIV virus.
- You are taking certain medications that are not permitted alongside the trial drugs afatinib or gefitinib (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Boehringer Ingelheim, Boehringer Ingelheim
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 7 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-free Survival; Time to Treatment Failure (TTF) (Main Overall Survival Analysis Cut-off Date, 08 April 2016); Overall Survival
Other options
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.